Towards Safer Drug Treatment
and Enhanced Patient Empowerment

Institute for Molecular Medicine Finland, University of Helsinki

The University of Helsinki, founded in 1640, is one of the best multidisciplinary research universities in the world and is an international academic community of 40,000 students and researchers. FIMM is a translational research institute focusing on human genomics and precision medicine at the Helsinki Institute of Life Science of the University of Helsinki. FIMM has a driving mission to perform innovative research on patients and populations targeted towards understanding drivers of health and disease and delivering improvements to the safety, efficacy, and efficiency of healthcare in Finland and beyond. FIMM has > 250 employees representing almost 30 nationalities and a budget of nearly 30 million €, with the great majority coming from external grants. FIMM is the Finnish node of the Nordic EMBL Partnership for Molecular Medicine.

Role within SafePolyMed

UH-FIMM participates in WP1 "Patients at Risk Score". Together with SafePolyMed partners, UH-FIMM will develop a novel, evidence-based risk score model for individual patients based on large real-world datasets and combining multiple factors (including polygenic risk scores).

Main contacts

Photo of Professor Samuli Ripatti
Professor Samuli Ripatti

Team Leader UH-FIMM

Photo of Professor Aarno Palotie
Professor Aarno Palotie